Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Mesenchymal stem cells show promise in easing MG muscle weakness

  Mesenchymal stem cells can calm immune system attacks and slow the muscle wasting seen in MG, potentially improving strength and endurance.

• Researchers uncover platelets’ role in driving myasthenia gravis activity

  Platelets are more than blood-clotting cells; they actively influence the immune system in untreated myasthenia gravis, worsening symptoms.

• Study finds patients with myasthenia gravis carried heavy anxiety burden in pandemic

  Patients with myasthenia gravis faced significant health-related anxiety during COVID-19, especially due to infection and treatment risks.

• New research drives personalized care for myasthenia gravis

  Doctors are learning that different types of myasthenia gravis respond better to treatments designed for each specific subtype.

• Researchers uncover distinct immune drivers in late-onset myasthenia gravis

  Late-onset myasthenia gravis showed different immune activity than early-onset cases, suggesting unique disease mechanisms.

• Researchers uncover new pathway driving myasthenia gravis progression

  Age-associated B cells were found to increase alongside worsening symptoms in patients with MG, suggesting a new way to measure severity.

• Study finds efgartigimod helps cut steroid use while boosting daily function in MG

  Many people with generalized myasthenia gravis were able to reduce or completely stop steroid treatment after starting efgartigimod.

• Recognizing nonmotor symptoms may improve life for people with MG

  Nonmotor symptoms such as cognitive problems and sensory loss are common in myasthenia gravis and can significantly affect daily life.

• Study recommends providing caregivers more support to help MG families thrive

  Caregivers for people with myasthenia gravis (MG) face emotional, physical and financial challenges that affect their own health.

• New tool shows difference in side effect severity for MG treatments

  Patients with MG who took prednisone and azathioprine experienced more treatment side effects than those on prednisone alone.